Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14266758 | 0.93 | LMNA (0.47) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL12349938 | 0.78 | LMNA (0.49) | LMNANPC1RAB9APOLB | |
| SCHEMBL12358259 | 0.78 | LMNA (0.49) | LMNANPC1RAB9APOLB | |
| SCHEMBL2603297 | 0.78 | LMNA (0.49) | LMNANPC1RAB9APOLB | |
| SCHEMBL17001873 | 0.78 | LMNA (0.46) | LMNANPC1RAB9APOLBCHRM2 | |
| SCHEMBL7018542 | 0.76 | SMN1; SMN2 (0.39) | LMNANPC1RAB9A | |
| SCHEMBL2656962 | 0.73 | MAPT (0.55) | LMNAPOLB | |
| SCHEMBL24164197 | 0.73 | CHRNB2 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL2240430 | 0.72 | LMNA (0.44) | LMNANPC1RAB9APOLB | |
| SCHEMBL2239093 | 0.72 | LMNA (0.44) | LMNANPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190169193-A1 | Method of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds | ARRAY BIOPHARMA INC. | 2019-06-06 | — | — | US | disclosed |
| US-9795611-B2 | Method of treatment using substituted imidazo[1,2b]pyridazine compounds | ARRAY BIOPHARMA, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796723-B2 | Method of treatment using substituted imidazo[1,2b]pyridazine compounds | ARRAY BIOPHARMA, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| WO-2017112777-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
| US-9676783-B2 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | ARRAY BIOPHARMA, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170114067-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170112849-A1 | Method of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds | ARRAY BIOPHARMA, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114068-A1 | Method of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds | ARRAY BIOPHARMA, INC. | 2017-04-27 | — | — | US | disclosed |
| US-9447104-B2 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds | ARRAY BIOPHARMA, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-8299063-B2 | Amido-thiophene compounds and their use | THE UNIVERSITY OF EDINBURGH (GB) | 2012-10-30 | — | — | US | disclosed |
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | THE UNIVERSITY OF EDINBURGH (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20110015178-A1 | Amido-Thiophene Compounds and Their Use | THE UNIVERSITY OF EDINBURGH (GB) | 2011-01-20 | — | — | US | disclosed |
| US-7858796-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-7858796-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| WO-2009112845-A1 | AMIDO-THIOPHENE COMPOUNDS AND THEIR USE | THE UNIVERSITY OF EDINBURGH (GB) | 2009-09-17 | — | — | WO | disclosed |
| US-20080058312-A1 | Modulators of hepatocyte growth factor/c-Met activity | ANGION BIOMEDICA CORPORATION (US) | 2008-03-06 | — | — | US | disclosed |
| US-20070254873-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| US-20070254873-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| WO-1995004052-A1 | METHYLGUANIDINE DERIVATIVES, METHODS FOR PREPARING SAME AND COMPOSITIONS CONTAINING SAID DERIVATIVES | SANOFI (FR) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | HSD11B1, HSD11B2, HSD3B1 | CHRNB2 1125/4885CHRNB4 1878/4885CHRNA3 1094/4885 |
| US-20170114068-A1 | Method of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds | COL2A1, COL1A1, IFNAR1 | CHRNB2 154/4885CHRNB4 375/4885CHRNA3 208/4885 |
| US-20170112849-A1 | Method of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds | COL2A1, COL1A1, IFNAR1 | CHRNB2 154/4885CHRNB4 375/4885CHRNA3 208/4885 |
| US-20110015178-A1 | Amido-Thiophene Compounds and Their Use | HSD11B1, HSD11B2, HSD17B1 | CHRNB2 1734/4885CHRNB4 2745/4885CHRNA3 2195/4885 |
| US-20170114067-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | CHRNB2 1219/4885CHRNB4 1569/4885CHRNA3 467/4885 |
| US-20190169193-A1 | Method of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds | COL2A1, COL1A1, IFNAR1 | CHRNB2 154/4885CHRNB4 375/4885CHRNA3 208/4885 |
| US-20070254873-A1 | Chemical Compounds | IKBKG, NFKBIA, RELA | CHRNB2 781/4885CHRNB4 2041/4885CHRNA3 1411/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | CHRNB2 4681/4885CHRNB4 4670/4885CHRNA3 4779/4885 |
| US-20080058312-A1 | Modulators of hepatocyte growth factor/c-Met activity | HGF, MET, HDGF | CHRNB2 4710/4885CHRNB4 4778/4885CHRNA3 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.